L-Type amino acid transporter 1: prognostic marker and therapeutic target in lung cancer

L-Type amino acid transporter 1 (LAT1) is highly expressed in various cancer cells, including lung cancer. However, its inhibition remains unclear. We used tissue microarrays (TMAs) from surgically resected lung cancer and autopsy specimens to assess LAT1 expression frequency and inter-tumor heterogeneity using immunohistochemistry. Additionally, we assessed the combined effects of targeted drugs and LAT1 inhibition in vitro and in vivo using human lung cancer cell lines. Among 127 lung cancer cases (96 TMAs and 31 autopsy specimens), LAT1 expression was observed in 36% (20/55) of small cell carcinomas, 90% (27/30) of squamous cell carcinomas, and 31% (13/42) of adenocarcinomas, including 33% (6/18) of driver mutation-positive adenocarcinomas. LAT1-positive cases had significantly shorter postoperative disease-free survival (DFS) (p = 0.005; hazard ratio [HR] = 3.703). LAT1 expression in autopsy specimens exhibited minimal intertumor heterogeneity in small cell and squamous cell carcinomas, with higher variability in adenocarcinomas. In human KRASG12C mutant lung cancer cell lines, the LAT1 inhibitor (JPH203) was ineffective as a single agent but synergistically increased the sensitivity of H23 and H2030 cell lines to the KRASG12C inhibitor (sotorasib) in vitro. In the H2030 xenograft model, JPH203 combined with sotorasib delayed tumor regrowth than that with sotorasib alone. These results indicate that LAT1 may be a therapeutic target in certain lung cancers, such as those with KRASG12C mutations.

Authors

Institutions

Publication Details

Journal
Cancer Research Communications
Published
2026-11-19
DOI
https://doi.org/10.1158/2767-9764.crc-26-0461
Primary Topic
Amino Acid Enzymes and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

L-Type amino acid transporter 1: prognostic marker and therapeutic target in lung cancer

Yuichi Tambo, T. Nguyen Huy, Seiji Yano, Shigeki Nanjo et al.
Cancer Research Communications
Amino Acid Enzymes and Metabolism
article

L-Type amino acid transporter 1: prognostic marker and therapeutic target in lung cancer

Yuichi Tambo, T. Nguyen Huy, Seiji Yano, Shigeki Nanjo, Satoshi Watanabe, Koji Fukuda, Masafumi Horie, Yuri Murase, Hiroshi Nishihara, Shunichi Nomura, Tsukasa Ueda, Hayato Koba, Yukinobu Ito, Takahiro Shimizu, Sachiko Arai
article en

Abstract

L-Type amino acid transporter 1 (LAT1) is highly expressed in various cancer cells, including lung cancer. However, its inhibition remains unclear. We used tissue microarrays (TMAs) from surgically resected lung cancer and autopsy specimens to assess LAT1 expression frequency and inter-tumor heterogeneity using immunohistochemistry. Additionally, we assessed the combined effects of targeted drugs and LAT1 inhibition in vitro and in vivo using human lung cancer cell lines. Among 127 lung cancer cases (96 TMAs and 31 autopsy specimens), LAT1 expression was observed in 36% (20/55) of small cell carcinomas, 90% (27/30) of squamous cell carcinomas, and 31% (13/42) of adenocarcinomas, including 33% (6/18) of driver mutation-positive adenocarcinomas. LAT1-positive cases had significantly shorter postoperative disease-free survival (DFS) (p = 0.005; hazard ratio [HR] = 3.703). LAT1 expression in autopsy specimens exhibited minimal intertumor heterogeneity in small cell and squamous cell carcinomas, with higher variability in adenocarcinomas. In human KRASG12C mutant lung cancer cell lines, the LAT1 inhibitor (JPH203) was ineffective as a single agent but synergistically increased the sensitivity of H23 and H2030 cell lines to the KRASG12C inhibitor (sotorasib) in vitro. In the H2030 xenograft model, JPH203 combined with sotorasib delayed tumor regrowth than that with sotorasib alone. These results indicate that LAT1 may be a therapeutic target in certain lung cancers, such as those with KRASG12C mutations.

Cancer Research Communications
Kanazawa University (JP), Keio University (JP), Kanazawa University Hospital (JP), Keio University Hospital (JP), Kobe University (JP)
Amino Acid Enzymes and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon